Registration - Amendment

GLENMARK PHARMACEUTICALS USA for GLENMARK PHARMACEUTICALS USA

Firm
Client
Income
—
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

FDA User Fees, Tax Reform, Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GRANT ERDEL New Legislative Correspondent - Senator Bond Administrative Assistant - Representative Jo Ann Emerson Senior Policy Advisor - Representative Charles Bass

Health Issues HCR

FDA User Fees, Tax Reform, Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GRANT ERDEL New Legislative Correspondent - Senator Bond Administrative Assistant - Representative Jo Ann Emerson Senior Policy Advisor - Representative Charles Bass

Copyright/Patent/Trademark CPT

FDA User Fees, Tax Reform, Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GRANT ERDEL New Legislative Correspondent - Senator Bond Administrative Assistant - Representative Jo Ann Emerson Senior Policy Advisor - Representative Charles Bass

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
GLENMARK PHARMACEUTICALS India India 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.